MARK BRUDER: Open Payments
NPI 1609864180 · YORK, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,046 in 47 payments from 10 companies in 2025. Trend: 2023 $1,356 · 2024 $1,121 · 2025 $1,046
Food & beverage: $1,046
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $314 |
| GlaxoSmithKline, LLC. | 18 | $310 |
| Amgen Inc. | 5 | $136 |
| Novartis Pharmaceuticals Corporation | 4 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| GENZYME CORPORATION | 2 | $51 |
| Blueprint Medicines Corporation | 1 | $35 |
| Grifols USA, LLC | 1 | $29 |
| Genentech USA, Inc. | 1 | $16 |
| Organon LLC | 1 | $13 |
Products named: NUCALA, AIRSUPRA, TEZSPIRE, FASENRA, TRELEGY ELLIPTA, DUPIXENT, Rhapsido, AYVAKIT.
Industry payments across PA — which companies pay providers there.
